<DOC>
	<DOCNO>NCT00008034</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell shrink tumor remove surgery . PURPOSE : Phase I trial study effectiveness combination chemotherapy surgery treat woman locally advance , inflammatory , large surgically removable breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Before Surgery Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity neoadjuvant capecitabine , cyclophosphamide , epirubicin woman locally advance inflammatory large operable breast cancer . II . Determine maximum tolerate dose regimen patient population . OUTLINE : This multicenter dose escalation study capecitabine . Patients receive neoadjuvant cyclophosphamide IV epirubicin IV day 1 oral capecitabine twice daily day 1-14 . Treatment continue every 21 day maximum 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 3-33 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm carcinoma breast Locally advance inflammatory disease ( T4 , N T , N2 N3 T4d ) OR Large operable disease ( large T2 T3 tumor shrinkage need ) No distant metastasis chest xray , liver ultrasound , bone scan except ipsilateral supraclavicular node No abnormal bone scintigrams confirm benign Hormone Receptor Status Not specify PATIENT CHARACTERISTICS : Age : 18 70 Sex : Female Menopausal status : Not specify Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : LVEF normal echocardiography MUGA Other : Not pregnant nursing Fertile patient must use effective contraception No serious uncontrolled illnesses No uncontrolled psychiatric addictive disorder No concurrent prior malignancy within past 5 year except adequately treat basal squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>